|
|
 |
|
Viewing report
|
|
|
|
Treatment Algorithms: Rheumatoid Arthritis 2nd Edition - Dmards Move to Front of Pack
Datamonitor, Nov 2002, Pages: 227
Rheumatoid arthritis is a debilitating disease that involves the inflammation of the lining of the joints. While no cure exists, physicians can utilize a number of strategies and products in an attempt to control the disesase and the accompanying pain and swelling. Based on 245 physician interviews, this analysis examines current treatment trends in the ongoing fight against rheumatoid arthritis.Covers the seven major pharmaceutical markets: US, Japan, France, Germany, Italy, Spain, and the UKThe drug classes covered include Dmards, biologics, traditional Nsaids, Cox-ii inhibitors, immunosuppressants, and oral and injectable steroidsTreatment strategies vary from country to country in terms of use of biologics and Dmards, particularly with regard to mild and moderate RA casesRheumatoid arthritis is an uncurable disease. However, the availability of Dmards and biologics have allowed physicians the opportunity to slow progression of the disease and improve the patient's condition from an early stage. Across all markets, physicians are using Dmards and combinations of them to treat mild and moderate RA patients in an attempt to control the arthritis from diagnosis.Despite the highly specialized nature of rheumatoid arthritis treatment, the majority of patients in all markets except Japan initially present their RA symptoms to primary care physicians. As a result, these physicians play a vital role in the treatment and referral of rheumatoid arthritis patients companies must continue to encourage awareness and understanding of the disease at a primary care level, to ensure maximum diagnosis.The battle between Enbrel and Remicade for sales within the biologic Dmard drug class has become the focus of the RA market in the past year. A number of factors have influenced physician choice during this period, including availability and method of administration, and as a result the success of each product has varied significantly from market to market.Understand treatment trends across seven markets, by disease severity, to evaluate potential for current and pipeline productsAssess the current and perceived role of biologic Dmards in the treatment of RA, amidst varied market challengesEvaluate markets where the patient population or use of a drug class is underpenetrated, in order to best position your productsIdentify the leading products in each market to build an understanding of the factors that contribute to success on the RA market in each country
Customers who bought this item also bought
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Competition For The Anti-TNF Failure Patient Population Increases
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Rheumatoid Arthritis Drug Discoveries: What The Future Holds
The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis
Stakeholder Insight: Rheumatoid Arthritis - Biologics Battle Up the Treatment Algorithm
Stakeholder Insight: Rheumatoid Arthritis - DMARDs Gain Ground as Biologics Competition Intensifies
Commercial Insight: Osteoarthritis and Rheumatoid Arthritis - New Growth In A Mature Market
US market size for methotrexate and anti-TNF rheumatoid arthritis therapies by number of patients, with total rheumatoid arthritis population, number of people diagnosed, and number of RA suffers treated with pharmaceuticals
Treatment Algorithms 2000: Rheumatoid Arthritis - Defining Changing Treatment Trends
Commercial and Pipeline Perspectives: Rheumatoid Arthritis - Novel Biologics Drive Innovation in the Global RA Market
Disease Modification in Rheumatoid Arthritis - The Biologics Boom
Rheumatoid Arthritis: Market Trends and R&D Insights
|
|
|
|
